Hotpennystocknews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 01/21/2014 -- Hotpennystocknews.com issues special report on - PeopleString Corporation (PLPED),Provectus Biopharmaceuticals (OTCMKTS:PVCT),Capital Properties, Inc.(OTCMKTS:CPTP),Destiny (OTCMKTS:DSNY)
PeopleString Corporation (PLPED) has developed and operates a social network with a multi-tiered affiliate program that shares revenue the Company generates through the social network with PeopleString's users. We share revenue generated from advertising and marketing affiliations with the active users of our social network, which are defined as those users who are registered users and have logged onto their account within 30 days (or 90 days for premium users) of the date that the revenue is received. In addition, pursuant to our shopping rewards program, a user who purchases through our website will share in the revenue received by us as a result of such purchases. In addition to our free user accounts, we offer premium services that may be purchased by our users, including web development.
PLPED finished last trade at $4.70, losing -13.76%. Trading volume recorded for this company was about 40,373.00 shares as compared to its average volume of 39,322.00 shares. The share price plunged almost -72.39% in the last one month while its 52 week high is $40.00. Its market capitalization is now about $8.53 million.
Why Should Investors Buy PLPED After the Recent Fall? Just Go Here and Find Out.
Provectus Biopharmaceuticals (OTCMKTS:PVCT) specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.
PVCT opened the session at $2.85, trading in a range of $2.71 - $2.93. The stock showed a positive performance of +10.15% in the last trading session from its previous close of $2.66 and closed at $2.93. The stock traded on a volume of 2.13 million shares and the average volume of the stock remained 2.12 million shares.
Is Investor Showing Any Interest On PVCT ? Find Out Here.
Capital Properties, Inc.(OTCMKTS:CPTP), through its subsidiaries, engages in owning and leasing properties in Rhode Island. The company operates through two segments, Leasing and Petroleum Storage. The Leasing segment owns approximately 18 acres in the Capital Center area in downtown Providence, Rhode Island. It also leases outdoor advertising locations for billboards along interstate and primary highways in Rhode Island and Massachusetts. The Petroleum Storage segment owns a petroleum storage terminal with a capacity of approximately 1,000,000 barrels in East Providence, Rhode Island.
More Details On CPTP.
Universal, EMI, Warner, Sony and one thousand other labels use Destiny's (OTCMKTS:DSNY) secure distribution service to deliver most of their pre-release music to radio, online retail, DJ's, sports stadiums, journalists and VIP. Destiny's instant play streaming includes internet radio, internet TV, online surveys and new cloud and mobile offerings. Patents include watermarking, peer to peer locking and pending cross platform streaming video for mobile.
DSNY shares gain 29.66 percent to close at $1.88. The stock is down around-1.05% this year and 155.78% for the last 12 months. Around 656,972shares changed hands yesterday, higher from an-average trading volume of 197,679 shares.
Why Should Investors Buy DSNY After The Recent Gain? Just Go Here and Find Out.
Neither Hotpennystocknews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by Hotpennystocknews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.Hotpennystocknews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through Hotpennystocknews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in.
Read Full disclaimer at:http://www.hotpennystocknews.com/disclaimer.php
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)